Clinical Trial Update: Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients [Phase 2]

View source ↗

Summary

Phase II open-label trial evaluating tisagenlecleucel in pediatric non-Hodgkin lymphoma has completed and posted results in March 2024, assessing safety and eff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Kymriah (tisagenlecleucel)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-03-19